Generic competition and safety warnings cast mist over Horizant's horizons
This article was originally published in Scrip
FDA approval of Horizant (gabapentin enacarbil) offers patients with postherpetic neuralgia an improved dosing regimen over available treatment options. However, the Xenoport drug faces fierce competition in the US, where it will be marketed by GlaxoSmithKline, from generic gabapentin and the once daily gabapentin formulation Gralise from Depomed. Moreover, safety warnings surrounding driving impairments are likely to serve as a deterrent to prescribing.
You may also be interested in...
The recent Respiratory Effectiveness Group (REG) Summit provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. Dr Natasha Spiller was there to look at a new battle ground for top-selling mainstay respiratory therapies, Spiriva, Symbicort and Advair.
It has been an eventful week in chronic obstructive pulmonary disease (COPD). New safety data emerged for Spiriva Respimat (tiotropium; Boehringer Ingelheim) and encouraging analyses from Novartis’ LABA/LAMA Ultibro Breezhaler from the European Respiratory Society (ERS) Annual Congress: while Anoro (umeclidinium/vilanterol), GlaxoSmithKline’s fixed-dose long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) inhaler, has been recommended for approval by the US FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC).
The expected entry of Ultibro Breezhaler into the COPD market following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 25 July will considerably advance Novartis's position within the market.